Von Willebrand factor and aging

Area of Science:

• Hematology
• Cardiovascular Medicine
• Geriatrics

Background:

• Von Willebrand factor (VWF) is crucial for primary hemostasis and factor VIII stability.
• Increasing age correlates with higher VWF levels, a risk factor for venous thromboembolism and cardiovascular disease (CVD).
• Von Willebrand disease (VWD) presentation can vary with age, presenting challenges in bleeding management and treatment considerations for older adults.

Purpose of the Study:

• To explore the multifaceted roles of VWF in hemostasis and cardiovascular health.
• To examine the implications of aging on VWF levels and associated health risks.
• To discuss the complexities of managing VWD, particularly in aging patients with or at risk for CVD.

Main Methods:

• Review of existing literature on VWF physiology, age-related changes, and disease associations.
• Analysis of clinical implications for VWD patients, focusing on bleeding complications and therapeutic strategies.
• Examination of the interplay between VWD, aging, and cardiovascular disease management.

Main Results:

• Elevated VWF levels are linked to increased risks of venous thromboembolism and CVD.
• Aging can alter VWD symptom presentation, with gastrointestinal bleeding and hematuria being common concerns.
• Specific VWD treatments require caution in older patients; CVD management in VWD patients is complex.

Conclusions:

• VWF's role extends beyond hemostasis to cardiovascular health, with age being a significant modulating factor.
• Careful consideration of age-related changes and comorbidities is essential for effective VWD management.
• The interaction between VWD and CVD necessitates tailored treatment approaches, especially concerning antiplatelet therapies.